By William Ho (IN8bio)2024-02-28T10:06:21
Gamma delta (γδ) T cells comprise a distinct and powerful subpopulation of T cells, bridging innate and adaptive immunity, that holds great promise for treating cancer. IN8Bio co-founder and CEO William Ho and COO Kate Rochlin discuss what makes γδ T cells unique, how preclinical research suggests their antitumour activity ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2024-02-06T08:57:06
Sponsored by bit.bio
2024-02-08T11:07:39
Sponsored by Samplix ApS
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
2023-04-12T15:28:08
Sponsored by nanoComposix
2023-01-06T16:37:30
Sponsored by Catalent
2024-01-10T08:23:16
Sponsored by BellBrook Labs
Site powered by Webvision Cloud